Understanding resistance to amivantamab in lung cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study aims to evaluate the mechanisms of acquired resistance to amivantamab monotherapy in patients with advanced non-small cell lung cancer (NSCLC) who have an EGFR exon 20 insertion mutation. Participants will provide blood samples for circulating tumor DNA (ctDNA) analysis and, when available, tumor tissue samples for DNA next-generation sequencing (NGS) at the time of disease progression. The study seeks to identify how resistance develops and how it may inform future systemic therapies for these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients with advanced NSCLC with EGFR ins20 receiving amivantamab as monotherapy in France under ATU or EAP;
* Age ≥ 18 years;
* Histologically confirmed advanced NSCLC (metastatic or locally advanced unresectable and not suitable for definitive radiotherapy) with EGFR ins20;
* Patients included will be required to sign an informed consent form to collect blood samples (liquid biopsy) and tissue biopsy when available at progression on amivantamab;
* Confirmed progression on amivantamab according to RECIST 1.1;
* Patient enrolled in the french National Health Insurance program or with a third- party payer.

Exclusion Criteria:

* Patients receiving amivantamab in combination with another therapy;
* Patients who do not consent to liquid biopsy at progression.

Where it's running

• Centre Hospitalier du Morvan
  Brest, France Recruiting
• Pneumologie Centre Hospitalier Intercommunal de Créteil
  Créteil, France Recruiting
• Pneumologie, CHU Grenoble
  Grenoble, France Recruiting
• Oncologie thoracique Hôpital Nord
  Marseille, France Recruiting
• Hôpital Cochin
  Paris, France Recruiting
• Pneumologie, Hôpital Tenon
  Paris, France Recruiting

Study contacts

• Principal investigator: Pascale Tomasini — Service d'Oncologie Multidisciplinaire et Innovations Thérapeutiques Hôpital Nord-APHM
• Study coordinator: Laurent GRELLIER
• Email: laurent.greillier@ap-hm.fr
• Phone: +33 (0)4 91 96 59 01

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Amivantamab with platinum chemotherapy for metastatic EGFR‑mutant non‑small cell lung cancer

  This study will try giving amivantamab together with platinum chemotherapy to adults with metastatic NSCLC who have specific EGFR mutations to see how long their cancer stays controlled and how safe the treatment is.

  Recruiting at 11 sites Groupe Francais De Pneumo-Cancerologie · Aix-en-Provence and 15 other locations · NCT07563205

• BEBT-109 treatment for lung cancer with specific mutations

  This study is testing a new drug called BEBT-109 to see if it can help people with a specific type of lung cancer that has certain mutations, especially those who haven't had much success with other treatments.

  Recruiting at 2 sites Phase 2 BeBetter Med Inc · Guangzhou, Guangdong and 1 other locations · NCT06706713

• Assessing furmonertinib for lung cancer patients with specific mutations after surgery

  This study is testing if a new drug called furmonertinib can help lung cancer patients with specific mutations stay cancer-free after their surgery.

  Recruiting Phase 2 Sichuan Cancer Hospital and Research Institute · Chengdu, Sichuan · NCT06192849

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.